Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Marker Therapeutics Inc(MRKR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MRKR
10/19/2026: MRKR (1-star) is currently NOT-A-BUY. Pass it for now.
Marker Therapeutics is a clinical-stage biotechnology company focused on developing T cell immunotherapies, specifically targeting hematological and solid tumors. Its primary strength lies in its proprietary MultiTAA platform, which aims to provide effective treatments with lower manufacturing complexity and potentially better safety profiles than existing CAR-T therapies. The main investment story rests on the success of its lead candidate, MT-601, and the potential to partner with larger industry players. However, investors face significant risks, including ongoing financial losses, heavy dilution, and the high uncertainty of clinical trial success. This stock is best suited for speculative, high-risk investors who should closely monitor clinical data releases and financing developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential dependent on clinical success. |
| Momentum investor | Weak fit | The stock lacks sustained upward momentum and is prone to high volatility based on clinical news. |
| Value investor | Weak fit | The company has no earnings or tangible product revenue, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and is focused on capital preservation for R&D. |
| Low-risk investor | Weak fit | The stock is highly speculative and subject to significant price swings. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks often experience extreme price swings based on trial data and financing news. |
| Valuation risk | High | Determining value is difficult due to the lack of commercial revenue and reliance on long-term clinical prospects. |
| Competition risk (Cell Therapy) | High | The company competes with massive, well-capitalized firms in the crowded immuno-oncology space. |
| Business quality | Medium / high | As a clinical-stage developer, the quality depends entirely on the scientific viability of the platform. |
| Dividend income | Low / none | Investors should not expect any income generation from this equity. |
| Execution risk | High | Successfully navigating FDA requirements and clinical trial endpoints is inherently uncertain. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -70.38% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/19/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.34M USD | Price to earnings Ratio - | 1Y Target Price 7.87 |
Price to earnings Ratio - | 1Y Target Price 7.87 | ||
Volume (30-day avg) 131.8K shares | Beta 1.53 | 52 Weeks Range 0.84 - 2.46 | Updated Date 10/18/2026 |
52 Weeks Range 0.84 - 2.46 | Updated Date 10/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Researching and developing T cell therapies. | The company spends money on research and does not yet have products to sell. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9.34M | Price to Sales(TTM) 4.89 |
Enterprise Value 9.34M | Price to Sales(TTM) 4.89 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA -0.22 | Shares Outstanding 16.67M | Shares Floating 13.74M |
Shares Outstanding 16.67M | Shares Floating 13.74M | ||
Percent Insiders 5.49 | Percent Institutions 23.8 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.